ID   TRIPC_HUMAN             Reviewed;        1992 AA.
AC   Q14669; D4HL82; Q14CA3; Q14CF1; Q15644; Q53R87; Q53TE7;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 1.
DT   07-APR-2021, entry version 193.
DE   RecName: Full=E3 ubiquitin-protein ligase TRIP12;
DE            EC=2.3.2.26 {ECO:0000269|PubMed:18627766, ECO:0000269|PubMed:20208519, ECO:0000269|PubMed:30982744};
DE   AltName: Full=E3 ubiquitin-protein ligase for Arf;
DE            Short=ULF;
DE   AltName: Full=HECT-type E3 ubiquitin transferase TRIP12;
DE   AltName: Full=Thyroid receptor-interacting protein 12;
DE            Short=TR-interacting protein 12;
DE            Short=TRIP-12;
GN   Name=TRIP12; Synonyms=KIAA0045, ULF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, SUBCELLULAR LOCATION,
RP   INTERACTION WITH MYC AND CDKN2A, AND MUTAGENESIS OF CYS-1959.
RX   PubMed=20208519; DOI=10.1038/nature08820;
RA   Chen D., Shan J., Zhu W.G., Qin J., Gu W.;
RT   "Transcription-independent ARF regulation in oncogenic stress-mediated p53
RT   responses.";
RL   Nature 464:624-627(2010).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Bone marrow;
RX   PubMed=7584044; DOI=10.1093/dnares/1.5.223;
RA   Nomura N., Nagase T., Miyajima N., Sazuka T., Tanaka A., Sato S., Seki N.,
RA   Kawarabayasi Y., Ishikawa K., Tabata S.;
RT   "Prediction of the coding sequences of unidentified human genes. II. The
RT   coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of
RT   cDNA clones from human cell line KG-1.";
RL   DNA Res. 1:223-229(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1801-1992.
RX   PubMed=7776974; DOI=10.1210/mend.9.2.7776974;
RA   Lee J.W., Choi H.-S., Gyuris J., Brent R., Moore D.D.;
RT   "Two classes of proteins dependent on either the presence or absence of
RT   thyroid hormone for interaction with the thyroid hormone receptor.";
RL   Mol. Endocrinol. 9:243-254(1995).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1317, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [7]
RP   FUNCTION.
RX   PubMed=18627766; DOI=10.1016/j.bbrc.2008.07.019;
RA   Park Y., Yoon S.K., Yoon J.B.;
RT   "TRIP12 functions as an E3 ubiquitin ligase of APP-BP1.";
RL   Biochem. Biophys. Res. Commun. 374:294-298(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-310; SER-312; SER-991;
RP   SER-997; SER-1317 AND SER-1322, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   FUNCTION.
RX   PubMed=19028681; DOI=10.1074/jbc.m807554200;
RA   Park Y., Yoon S.K., Yoon J.B.;
RT   "The HECT domain of TRIP12 ubiquitinates substrates of the ubiquitin fusion
RT   degradation pathway.";
RL   J. Biol. Chem. 284:1540-1549(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-312; SER-991; SER-1317 AND
RP   SER-1322, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH SMARCC1.
RX   PubMed=20829358; DOI=10.1074/jbc.m110.173997;
RA   Keppler B.R., Archer T.K.;
RT   "Ubiquitin-dependent and ubiquitin-independent control of subunit
RT   stoichiometry in the SWI/SNF complex.";
RL   J. Biol. Chem. 285:35665-35674(2010).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-77; SER-312 AND SER-942, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-12; SER-310; SER-1030; SER-1317 AND SER-1322, CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [17]
RP   FUNCTION.
RX   PubMed=22884692; DOI=10.1016/j.cell.2012.06.039;
RA   Gudjonsson T., Altmeyer M., Savic V., Toledo L., Dinant C., Grofte M.,
RA   Bartkova J., Poulsen M., Oka Y., Bekker-Jensen S., Mailand N., Neumann B.,
RA   Heriche J.K., Shearer R., Saunders D., Bartek J., Lukas J., Lukas C.;
RT   "TRIP12 and UBR5 Suppress Spreading of Chromatin Ubiquitylation at Damaged
RT   Chromosomes.";
RL   Cell 150:697-709(2012).
RN   [18]
RP   INTERACTION WITH TRADD.
RX   PubMed=22561347; DOI=10.1038/ncb2496;
RA   Chio I.I., Sasaki M., Ghazarian D., Moreno J., Done S., Ueda T., Inoue S.,
RA   Chang Y.L., Chen N.J., Mak T.W.;
RT   "TRADD contributes to tumour suppression by regulating ULF-dependent p19Arf
RT   ubiquitylation.";
RL   Nat. Cell Biol. 14:625-633(2012).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-12; SER-100; SER-312;
RP   SER-942; SER-991 AND SER-997, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1317 AND SER-1322, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   INVOLVEMENT IN CLABARS, AND VARIANTS CLABARS LEU-5; 338-ARG--SER-1992 DEL;
RP   352-ARG--SER-1992 DEL; VARIANT VAL-761; HIS-1557; GLN-1595 AND LEU-1840.
RX   PubMed=27848077; DOI=10.1007/s00439-016-1743-x;
RA   Bramswig N.C., Luedecke H.J., Pettersson M., Albrecht B., Bernier R.A.,
RA   Cremer K., Eichler E.E., Falkenstein D., Gerdts J., Jansen S., Kuechler A.,
RA   Kvarnung M., Lindstrand A., Nilsson D., Nordgren A., Pfundt R., Spruijt L.,
RA   Surowy H.M., de Vries B.B., Wieland T., Engels H., Strom T.M.,
RA   Kleefstra T., Wieczorek D.;
RT   "Identification of new TRIP12 variants and detailed clinical evaluation of
RT   individuals with non-syndromic intellectual disability with or without
RT   autism.";
RL   Hum. Genet. 136:179-192(2017).
RN   [22]
RP   INVOLVEMENT IN CLABARS, AND VARIANTS CLABARS VAL-761 AND PRO-1449--SER-1992
RP   DEL.
RX   PubMed=28251352; DOI=10.1007/s00439-017-1763-1;
RA   Zhang J., Gambin T., Yuan B., Szafranski P., Rosenfeld J.A., Balwi M.A.,
RA   Alswaid A., Al-Gazali L., Shamsi A.M.A., Komara M., Ali B.R., Roeder E.,
RA   McAuley L., Roy D.S., Manchester D.K., Magoulas P., King L.E., Hannig V.,
RA   Bonneau D., Denomme-Pichon A.S., Charif M., Besnard T., Bezieau S.,
RA   Cogne B., Andrieux J., Zhu W., He W., Vetrini F., Ward P.A., Cheung S.W.,
RA   Bi W., Eng C.M., Lupski J.R., Yang Y., Patel A., Lalani S.R., Xia F.,
RA   Stankiewicz P.;
RT   "Haploinsufficiency of the E3 ubiquitin-protein ligase gene TRIP12 causes
RT   intellectual disability with or without autism spectrum disorders, speech
RT   delay, and dysmorphic features.";
RL   Hum. Genet. 136:377-386(2017).
RN   [23]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=30982744; DOI=10.1016/j.molcel.2019.03.018;
RA   Kweon S.M., Chen Y., Moon E., Kvederaviciute K., Klimasauskas S.,
RA   Feldman D.E.;
RT   "An adversarial DNA N6-methyladenine-sensor network preserves Polycomb
RT   silencing.";
RL   Mol. Cell 74:1138-1147(2019).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase involved in ubiquitin fusion
CC       degradation (UFD) pathway and regulation of DNA repair
CC       (PubMed:19028681, PubMed:22884692). Part of the ubiquitin fusion
CC       degradation (UFD) pathway, a process that mediates ubiquitination of
CC       protein at their N-terminus, regardless of the presence of lysine
CC       residues in target proteins (PubMed:19028681). Acts as a key regulator
CC       of DNA damage response by acting as a suppressor of RNF168, an E3
CC       ubiquitin-protein ligase that promotes accumulation of 'Lys-63'-linked
CC       histone H2A and H2AX at DNA damage sites, thereby acting as a guard
CC       against excessive spreading of ubiquitinated chromatin at damaged
CC       chromosomes (PubMed:22884692). In normal cells, mediates ubiquitination
CC       and degradation of isoform p19ARF/ARF of CDKN2A, a lysine-less tumor
CC       suppressor required for p53/TP53 activation under oncogenic stress
CC       (PubMed:20208519). In cancer cells, however, isoform p19ARF/ARF and
CC       TRIP12 are located in different cell compartments, preventing isoform
CC       p19ARF/ARF ubiquitination and degradation (PubMed:20208519). Does not
CC       mediate ubiquitination of isoform p16-INK4a of CDKN2A
CC       (PubMed:20208519). Also catalyzes ubiquitination of NAE1 and SMARCE1,
CC       leading to their degradation (PubMed:18627766). Ubiquitination and
CC       degradation of target proteins is regulated by interaction with
CC       proteins such as MYC, TRADD or SMARCC1, which disrupt the interaction
CC       between TRIP12 and target proteins (PubMed:20829358). Mediates
CC       ubiquitination of ASXL1: following binding to N(6)-methyladenosine
CC       methylated DNA, ASXL1 is ubiquitinated by TRIP12, leading to its
CC       degradation and subsequent inactivation of the PR-DUB complex
CC       (PubMed:30982744). {ECO:0000269|PubMed:18627766,
CC       ECO:0000269|PubMed:19028681, ECO:0000269|PubMed:20208519,
CC       ECO:0000269|PubMed:20829358, ECO:0000269|PubMed:22884692,
CC       ECO:0000269|PubMed:30982744}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.26; Evidence={ECO:0000269|PubMed:18627766,
CC         ECO:0000269|PubMed:20208519, ECO:0000269|PubMed:30982744};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:18627766, ECO:0000269|PubMed:20208519,
CC       ECO:0000269|PubMed:30982744}.
CC   -!- SUBUNIT: Interacts with MYC; leading to disrupt interaction with
CC       isoform p19ARF/ARF of CDKN2A (PubMed:20208519). Interacts with TRADD;
CC       leading to disrupt interaction with isoform p19ARF/ARF of CDKN2A
CC       (PubMed:22561347). Interacts with SMARCC1; leading to disrupt
CC       interaction with SMARCE1 (PubMed:20829358).
CC       {ECO:0000269|PubMed:20208519, ECO:0000269|PubMed:20829358,
CC       ECO:0000269|PubMed:22561347}.
CC   -!- INTERACTION:
CC       Q14669; Q8N726: CDKN2A; NbExp=4; IntAct=EBI-308443, EBI-625922;
CC       Q14669; P49286: MTNR1B; NbExp=3; IntAct=EBI-308443, EBI-1188341;
CC       Q14669; P01106: MYC; NbExp=7; IntAct=EBI-308443, EBI-447544;
CC       Q14669; P06748-1: NPM1; NbExp=2; IntAct=EBI-308443, EBI-354150;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleoplasm
CC       {ECO:0000269|PubMed:20208519}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q14669-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q14669-2; Sequence=VSP_044328, VSP_044329;
CC       Name=3;
CC         IsoId=Q14669-3; Sequence=VSP_044326, VSP_044328;
CC       Name=4;
CC         IsoId=Q14669-4; Sequence=VSP_044327, VSP_044328, VSP_044329;
CC   -!- DISEASE: Clark-Baraitser syndrome (CLABARS) [MIM:617752]: An autosomal
CC       dominant disease characterized by intellectual disability, delayed
CC       psychomotor development, behavioral abnormalities, variable dysmorphic
CC       facial features, tall stature, obesity, and macrocephaly.
CC       {ECO:0000269|PubMed:27848077, ECO:0000269|PubMed:28251352}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the UPL family. K-HECT subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAY14681.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=AAY14755.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=BAA05837.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; EU489742; ACC99349.1; -; mRNA.
DR   EMBL; D28476; BAA05837.2; ALT_INIT; mRNA.
DR   EMBL; AC009973; AAY14755.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC093384; AAY14681.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC105380; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC114556; AAI14557.1; -; mRNA.
DR   EMBL; BC113891; AAI13892.1; -; mRNA.
DR   EMBL; L40383; AAC41731.1; -; mRNA.
DR   CCDS; CCDS33391.1; -. [Q14669-1]
DR   CCDS; CCDS63145.1; -. [Q14669-4]
DR   CCDS; CCDS63146.1; -. [Q14669-3]
DR   RefSeq; NP_001271143.1; NM_001284214.1. [Q14669-3]
DR   RefSeq; NP_001271144.1; NM_001284215.2. [Q14669-2]
DR   RefSeq; NP_001271145.1; NM_001284216.1. [Q14669-4]
DR   RefSeq; NP_001335244.1; NM_001348315.1. [Q14669-3]
DR   RefSeq; NP_001335245.1; NM_001348316.1. [Q14669-2]
DR   RefSeq; NP_004229.1; NM_004238.2. [Q14669-1]
DR   BioGRID; 114731; 94.
DR   DIP; DIP-58584N; -.
DR   IntAct; Q14669; 46.
DR   MINT; Q14669; -.
DR   STRING; 9606.ENSP00000373696; -.
DR   iPTMnet; Q14669; -.
DR   MetOSite; Q14669; -.
DR   PhosphoSitePlus; Q14669; -.
DR   SwissPalm; Q14669; -.
DR   BioMuta; TRIP12; -.
DR   DMDM; 2499839; -.
DR   EPD; Q14669; -.
DR   jPOST; Q14669; -.
DR   MassIVE; Q14669; -.
DR   MaxQB; Q14669; -.
DR   PaxDb; Q14669; -.
DR   PeptideAtlas; Q14669; -.
DR   PRIDE; Q14669; -.
DR   ProteomicsDB; 60100; -. [Q14669-1]
DR   ProteomicsDB; 60316; -.
DR   ProteomicsDB; 60326; -.
DR   Antibodypedia; 34396; 71 antibodies.
DR   Ensembl; ENST00000283943; ENSP00000283943; ENSG00000153827. [Q14669-1]
DR   Ensembl; ENST00000389044; ENSP00000373696; ENSG00000153827. [Q14669-3]
DR   Ensembl; ENST00000389045; ENSP00000373697; ENSG00000153827. [Q14669-4]
DR   GeneID; 9320; -.
DR   KEGG; hsa:9320; -.
DR   UCSC; uc002vpw.3; human. [Q14669-1]
DR   CTD; 9320; -.
DR   DisGeNET; 9320; -.
DR   GeneCards; TRIP12; -.
DR   HGNC; HGNC:12306; TRIP12.
DR   HPA; ENSG00000153827; Low tissue specificity.
DR   MalaCards; TRIP12; -.
DR   MIM; 604506; gene.
DR   MIM; 617752; phenotype.
DR   neXtProt; NX_Q14669; -.
DR   OpenTargets; ENSG00000153827; -.
DR   PharmGKB; PA36985; -.
DR   VEuPathDB; HostDB:ENSG00000153827.13; -.
DR   eggNOG; KOG0168; Eukaryota.
DR   eggNOG; KOG0170; Eukaryota.
DR   GeneTree; ENSGT00940000156517; -.
DR   HOGENOM; CLU_000366_2_0_1; -.
DR   InParanoid; Q14669; -.
DR   OMA; HGFNMDS; -.
DR   OrthoDB; 34110at2759; -.
DR   PhylomeDB; Q14669; -.
DR   TreeFam; TF323674; -.
DR   BRENDA; 2.3.2.B9; 2681.
DR   BRENDA; 6.3.2.19; 2681.
DR   PathwayCommons; Q14669; -.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 9320; 68 hits in 1012 CRISPR screens.
DR   ChiTaRS; TRIP12; human.
DR   GeneWiki; TRIP12; -.
DR   GenomeRNAi; 9320; -.
DR   Pharos; Q14669; Tbio.
DR   PRO; PR:Q14669; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q14669; protein.
DR   Bgee; ENSG00000153827; Expressed in testis and 248 other tissues.
DR   ExpressionAtlas; Q14669; baseline and differential.
DR   Genevisible; Q14669; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; HDA:UniProtKB.
DR   GO; GO:0046966; F:thyroid hormone receptor binding; IDA:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IMP:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IEA:UniProtKB-KW.
DR   GO; GO:2000780; P:negative regulation of double-strand break repair; IMP:UniProtKB.
DR   GO; GO:1901315; P:negative regulation of histone H2A K63-linked ubiquitination; IMP:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB.
DR   GO; GO:2000779; P:regulation of double-strand break repair; IBA:GO_Central.
DR   GO; GO:0045995; P:regulation of embryonic development; ISS:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   CDD; cd00078; HECTc; 1.
DR   Gene3D; 1.25.10.10; -; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR000569; HECT_dom.
DR   InterPro; IPR035983; Hect_E3_ubiquitin_ligase.
DR   InterPro; IPR004170; WWE-dom.
DR   InterPro; IPR037197; WWE_dom_sf.
DR   Pfam; PF00632; HECT; 1.
DR   SMART; SM00119; HECTc; 1.
DR   SUPFAM; SSF117839; SSF117839; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   SUPFAM; SSF56204; SSF56204; 1.
DR   PROSITE; PS50237; HECT; 1.
DR   PROSITE; PS50918; WWE; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Autism spectrum disorder;
KW   Disease variant; DNA damage; DNA repair; Mental retardation; Nucleus;
KW   Phosphoprotein; Reference proteome; Transferase; Ubl conjugation pathway.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   CHAIN           2..1992
FT                   /note="E3 ubiquitin-protein ligase TRIP12"
FT                   /id="PRO_0000173872"
FT   DOMAIN          749..836
FT                   /note="WWE"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00248"
FT   DOMAIN          1885..1992
FT                   /note="HECT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00104"
FT   REGION          1496..1570
FT                   /note="K-box"
FT   ACT_SITE        1959
FT                   /note="Glycyl thioester intermediate"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         12
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         77
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         85
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:G5E870"
FT   MOD_RES         100
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         181
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:G5E870"
FT   MOD_RES         310
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         312
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         942
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         991
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         997
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1016
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F1LP64"
FT   MOD_RES         1030
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         1317
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1322
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1329
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:G5E870"
FT   MOD_RES         1376
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F1LP64"
FT   MOD_RES         1377
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:F1LP64"
FT   MOD_RES         1425
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:G5E870"
FT   MOD_RES         1427
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:G5E870"
FT   VAR_SEQ         32
FT                   /note="G -> GRSHLGQAKHKGYSPPESRKSNSKAPKVQSNTTSELSRGHLSK (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_044326"
FT   VAR_SEQ         33..335
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_044327"
FT   VAR_SEQ         380
FT                   /note="A -> AAASSSV (in isoform 2, isoform 3 and isoform
FT                   4)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:20208519"
FT                   /id="VSP_044328"
FT   VAR_SEQ         784
FT                   /note="E -> EAAHQVGEDEISLSTLGRVYTIDFNSMQ (in isoform 2 and
FT                   isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:20208519"
FT                   /id="VSP_044329"
FT   VARIANT         5
FT                   /note="P -> L (in CLABARS; unknown pathological
FT                   significance; dbSNP:rs1300458163)"
FT                   /evidence="ECO:0000269|PubMed:27848077"
FT                   /id="VAR_080431"
FT   VARIANT         338..1992
FT                   /note="Missing (in CLABARS; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:27848077"
FT                   /id="VAR_080432"
FT   VARIANT         352..1992
FT                   /note="Missing (in CLABARS; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:27848077"
FT                   /id="VAR_080433"
FT   VARIANT         761
FT                   /note="A -> V (in CLABARS; dbSNP:rs373429636)"
FT                   /evidence="ECO:0000269|PubMed:27848077,
FT                   ECO:0000269|PubMed:28251352"
FT                   /id="VAR_080434"
FT   VARIANT         1449..1992
FT                   /note="Missing (in CLABARS)"
FT                   /evidence="ECO:0000269|PubMed:28251352"
FT                   /id="VAR_080435"
FT   VARIANT         1557
FT                   /note="D -> H (in CLABARS)"
FT                   /evidence="ECO:0000269|PubMed:27848077"
FT                   /id="VAR_080436"
FT   VARIANT         1595
FT                   /note="R -> Q (in CLABARS; dbSNP:rs1553602821)"
FT                   /evidence="ECO:0000269|PubMed:27848077"
FT                   /id="VAR_080437"
FT   VARIANT         1840
FT                   /note="S -> L (in CLABARS; dbSNP:rs866079762)"
FT                   /evidence="ECO:0000269|PubMed:27848077"
FT                   /id="VAR_080438"
FT   MUTAGEN         1959
FT                   /note="C->A: Abolishes E3 ubiquitin-protein ligase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:20208519"
FT   CONFLICT        1969..1992
FT                   /note="SSIEIMREKLLIAAREGQQSFHLS -> QALRYA (in Ref. 5;
FT                   AAC41731)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        Q14669-2:380
FT                   /note="A -> T (in Ref. 1; ACC99349)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1992 AA;  220434 MW;  294A7C063A3332DE CRC64;
     MSNRPNNNPG GSLRRSQRNT AGAQPQDDSI GGRSCSSSSA VIVPQPEDPD RANTSERQKT
     GQVPKKDNSR GVKRSASPDY NRTNSPSSAK KPKALQHTES PSETNKPHSK SKKRHLDQEQ
     QLKSAQSPST SKAHTRKSGA TGGSRSQKRK RTESSCVKSG SGSESTGAEE RSAKPTKLAS
     KSATSAKAGC STITDSSSAA STSSSSSAVA SASSTVPPGA RVKQGKDQNK ARRSRSASSP
     SPRRSSREKE QSKTGGSSKF DWAARFSPKV SLPKTKLSLP GSSKSETSKP GPSGLQAKLA
     SLRKSTKKRS ESPPAELPSL RRSTRQKTTG SCASTSRRGS GLGKRGAAEA RRQEKMADPE
     SNQEAVNSSA ARTDEAPQGA AGAVGMTTSG ESESDDSEMG RLQALLEARG LPPHLFGPLG
     PRMSQLFHRT IGSGASSKAQ QLLQGLQASD ESQQLQAVIE MCQLLVMGNE ETLGGFPVKS
     VVPALITLLQ MEHNFDIMNH ACRALTYMME ALPRSSAVVV DAIPVFLEKL QVIQCIDVAE
     QALTALEMLS RRHSKAILQA GGLADCLLYL EFFSINAQRN ALAIAANCCQ SITPDEFHFV
     ADSLPLLTQR LTHQDKKSVE STCLCFARLV DNFQHEENLL QQVASKDLLT NVQQLLVVTP
     PILSSGMFIM VVRMFSLMCS NCPTLAVQLM KQNIAETLHF LLCGASNGSC QEQIDLVPRS
     PQELYELTSL ICELMPCLPK EGIFAVDTML KKGNAQNTDG AIWQWRDDRG LWHPYNRIDS
     RIIEQINEDT GTARAIQRKP NPLANSNTSG YSESKKDDAR AQLMKEDPEL AKSFIKTLFG
     VLYEVYSSSA GPAVRHKCLR AILRIIYFAD AELLKDVLKN HAVSSHIASM LSSQDLKIVV
     GALQMAEILM QKLPDIFSVY FRREGVMHQV KHLAESESLL TSPPKACTNG SGSMGSTTSV
     SSGTATAATH AAADLGSPSL QHSRDDSLDL SPQGRLSDVL KRKRLPKRGP RRPKYSPPRD
     DDKVDNQAKS PTTTQSPKSS FLASLNPKTW GRLSTQSNSN NIEPARTAGG SGLARAASKD
     TISNNREKIK GWIKEQAHKF VERYFSSENM DGSNPALNVL QRLCAATEQL NLQVDGGAEC
     LVEIRSIVSE SDVSSFEIQH SGFVKQLLLY LTSKSEKDAV SREIRLKRFL HVFFSSPLPG
     EEPIGRVEPV GNAPLLALVH KMNNCLSQME QFPVKVHDFP SGNGTGGSFS LNRGSQALKF
     FNTHQLKCQL QRHPDCANVK QWKGGPVKID PLALVQAIER YLVVRGYGRV REDDEDSDDD
     GSDEEIDESL AAQFLNSGNV RHRLQFYIGE HLLPYNMTVY QAVRQFSIQA EDERESTDDE
     SNPLGRAGIW TKTHTIWYKP VREDEESNKD CVGGKRGRAQ TAPTKTSPRN AKKHDELWHD
     GVCPSVSNPL EVYLIPTPPE NITFEDPSLD VILLLRVLHA ISRYWYYLYD NAMCKEIIPT
     SEFINSKLTA KANRQLQDPL VIMTGNIPTW LTELGKTCPF FFPFDTRQML FYVTAFDRDR
     AMQRLLDTNP EINQSDSQDS RVAPRLDRKK RTVNREELLK QAESVMQDLG SSRAMLEIQY
     ENEVGTGLGP TLEFYALVSQ ELQRADLGLW RGEEVTLSNP KGSQEGTKYI QNLQGLFALP
     FGRTAKPAHI AKVKMKFRFL GKLMAKAIMD FRLVDLPLGL PFYKWMLRQE TSLTSHDLFD
     IDPVVARSVY HLEDIVRQKK RLEQDKSQTK ESLQYALETL TMNGCSVEDL GLDFTLPGFP
     NIELKKGGKD IPVTIHNLEE YLRLVIFWAL NEGVSRQFDS FRDGFESVFP LSHLQYFYPE
     ELDQLLCGSK ADTWDAKTLM ECCRPDHGYT HDSRAVKFLF EILSSFDNEQ QRLFLQFVTG
     SPRLPVGGFR SLNPPLTIVR KTFESTENPD DFLPSVMTCV NYLKLPDYSS IEIMREKLLI
     AAREGQQSFH LS
//
